News & Updates

Women with a history of infertility are more likely to develop reproductive cancers that are related to obesity, as reported in a study.

The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.

Postdiagnostic use of low-dose zinc supplement may help reduce the risk of lethal prostate cancer and all-cause mortality among patients with nonmetastatic prostate cancer, suggests a recent study.

Intraoperative blood transfusion appears to increase the risk of venous thromboembolism (VTE) within 90 days following radical cystectomy among patients with bladder cancer, a study has shown.

Postoperative salvage radiotherapy (SRT) plus 6 months of androgen deprivation therapy (ADT) with abiraterone acetate/prednisone (AAP) and apalutamide (Apa) results in better progression-free (PFS) and metastasis-free survival (MFS) among patients with prostate cancer, findings from FORMULA-509 have shown. However, the primary analysis did not reach the prespecified threshold for statistical significance.

Treatment with stereotactic body radiation therapy (SBRT) followed by sorafenib results in better overall (OS) and progression-free survival (PFS), with no increase in adverse events (AEs), compared with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC), as shown in a phase III study presented at the 2023 ASCO GI Cancers Symposium.